Communiqués bioAffinity Technologies, Inc.

Actions

BIAF

US09076W4069

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 21:59:58 08/10/2026			Varia. 5j.	Varia. 1 janv.
5,640 ^USD	-8,44%		-7,24%	-67,80%

18:56	BioAffinity Technologies fixe à 4 millions de dollars le montant d’une offre directe enregistrée	MT
18:53	BioAffinity Technologies fixe le prix d’un placement direct enregistré de 4 millions de dollars	MT

Communiqués

18:08	BioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules	BU
14:05	BioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm	BU
07/10	BioAffinity Technologies Reports Over 100% Growth in CyPath(R) Lung Sales Through Third Quarter 2026	AQ
06/10	BioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026	BU
01/10	BioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL	AQ
30/09	BioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL	BU
22/09	BioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference	BU
18/09	BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath(R) Lung Noninvasive Lung Cancer Diagnostic	AQ
17/09	BioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic	BU
09/09	BioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements	BU
03/09	BioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	BU
02/09	BioAffinity Technologies Advances CyPath(R) Lung for Surveillance of Lung Cancer Survivors	AQ
02/09	Catalysts Emerge BIAF, LIDR, SSM, GMGMF to Watch Now	AQ
01/09	BioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors	BU
20/08	BioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026	BU
19/08	BioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath Lung	AQ
18/08	BioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung	BU
17/08	BioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules	AQ
14/08	BioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules	BU
13/08	BioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules	BU
07/08	BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung	BU
28/07	BioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath Lung	AQ
27/07	BioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung	BU
23/07	BioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD	AQ
22/07	BioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD	BU